Shao-Lee Lin, Acelyrin CEO

Ace­lyrin sets out for a 2021-sized IPO for Cal­i­for­nia biotech’s PhI­II drug

Drug li­cen­sor and de­vel­op­er Ace­lyrin re­vealed more of its IPO plans Mon­day morn­ing, map­ping out what could be one of the biggest biotech IPOs in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.